TRK is emerging as an actionable biomarker and oncogenic driver across a wide range of cancer types, including 1-3

Papillary thyroid, non-small cell lung, mammary analogue secretory carcinoma, breast, pancreatic, colorectal, and sarcoma (including gastrointestinal stromal tumor)

When present, TRK fusion is often the primary oncogenic driver, and may be mutually exclusive to other drivers. 1,4

TRK fusion cancer sites

Molecular tests for TRK fusion cancer include 1

  • Next-generation sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence in situ hybridization (FISH) 

Only testing can uncover TRK fusion cancer. 1

Test tube with double helix

Targeted therapies are being studied to advance treatment options for patients with actionable biomarkers—patients with TRK fusions need molecular testing to realize those options. 1,3

Double helix with humans